IHL
Director Trades
| Date | Director | Value |
|---|
Company News
Incannex Healthcare shareholders vote in favour of exclusive Nasdaq listing
Shareholders in Incannex Healthcare (ASX: IHL) (NASDAQ: IXHL) have voted overwhelmingly in favour of a scheme to redomicile the company’s headquarters to the US. Approximately 99.64% of shareholders and 99.93% of optionholders have given their nod of approval to the proposal which will see Incannex US acquire 100% of issued Incannex shares to become the […]
Incannex Healthcare to prepare FDA application for psilocybin-assisted psychotherapy program
Incannex Healthcare (ASX: IHL) subsidiary Psychennex Pty Ltd has started preparing an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for a psilocybin-assisted psychotherapy development program (Psi-GAD). The submission will include five detailed modules on the safety and efficacy of psilocybin-assisted psychotherapy across a range of mental health indications. The […]
Incannex Healthcare receives FDA clearance to start IHL-42X clinical trial on patients with obstructive sleep apnoea
Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has received approval from the US Food and Drug Administration (FDA) to conduct an investigational new drug (IND) opening trial for lead candidate IHL-42X in the US. The pivotal Phase 2/3 trial will assess the effect of IHL-42X in obstructive sleep apnoea (OSA) patients who are non-compliant, intolerant […]
Market wrap: plenty of underlying action as market moves sideways
At first glance, it appears not much happened on the Australian share market, which managed to eke out a 0.2% gain for the week after a 0.2% retreat on Friday. That is almost the textbook definition of sideways trading but looking further beneath the 17.9 point fall to 7339.5 points on the ASX 200 there […]
Incannex’s Clarion Clinics ready to open its doors for Australia’s first psychedelic treatment clinic
Incannex Healthcare’s (ASX: IHL) subsidiary, Clarion Clinics Group, has begun accepting registrations of interest from potential patients for two new psychedelic-assisted therapy (PAT) treatments at its website clarionclinics.com. The PAT treatments are intended to assist patients with treatment resistant depression (TRD) and post-traumatic stress disorder (PTSD) using psilocybin and MDMA in an Australian first clinic […]
Incannex completes pre-IND meeting with FDA over IHL-675A for treatment of rheumatoid arthritis
Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug (pre-IND) application meeting with the US Food and Drug Administration (FDA) relating to its proprietary drug product IHL-675A for the treatment of rheumatoid arthritis. The company submitted a meeting package in June which included a description of IHL-675A’s unique formulation, an overview of the proposed […]
Incannex submits key application to FDA for new treatment in $15 billion sleep apnoea market
Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has achieved another milestone with the development approval for new product targeting the $15 billion sleep apnoea market. An Investigational New Drug (IND) application has now been successfully submitted to the US Food and Drug Administration (FDA) for its unique IHL-42X development, a product it believes can relieve […]
Incannex Healthcare engages Fortrea to manage Phase 2/3 IHL-42X trial into obstructive sleep apnoea
Incannex Healthcare (ASX: IHL) has engaged global company Fortrea as the contract research organisation for management of its investigational new drug opening Phase 2/3 clinical trial investigating IHL-42X in the treatment of obstructive sleep apnoea. The trial will assess the safety and efficacy of IHL-42X at the best performing two doses from a recent proof-of-concept […]
Incannex Healthcare receives HREC approval for IHL-675A Phase 2 trial on patients with rheumatoid arthritis
Medicinal cannabinoid and psychedelic therapies development company Incannex Healthcare (ASX: IHL) has received approval from Bellberry Human Research Ethics Committee (HREC) to conduct a Phase 2 clinical trial of drug candidate IHL-675A at the premises of Emeritus Research in Victoria, Australia. The pivotal trial will assess the safety and efficacy of IHL-675A as a proprietary […]
Incannex Healthcare seeks exclusive NASDAQ listing in bid to expand horizons
Australian pharmaceutical cannabinoid product developer Incannex Healthcare (ASX: IHL) (NASDAQ: IXHL) has unveiled its intentions to relocate to the United States, with plans to eventually delist from the ASX. The company has elected to switch to the NASDAQ board as it believes the US market is more receptive to pharmaceutical programs. Incannex managing director and […]
Company Videos
Incannex Healthcare using medicinal cannabis to treat illnesses with unmet needs
Dr Sud Agarwal discusses the business strategy and medical advisory board at Impression Healthcare
The modus operandi of ASX listed Impression Healthcare
Impression Healthcare’s chief medical officer on traumatic brain injury and cannabinoids
Impression Healthcare’s Dr Sud Agarwal on obstructive sleep apnoea and cannabinoids
